Mariano Barbacid

In this Spanish name, the first or paternal surname is Barbacid and the second or maternal family name is Montalbán.

Mariano Barbacid
Barbacid in 2012
Born
Mariano Barbacid Montalbán

(1949-10-04) 4 October 1949
Madrid, Spain
EducationBiochemist
Alma materUniversidad Complutense de Madrid
OccupationCancer researcher
Known forIsolating the first oncogene

Mariano Barbacid Montalbán (born 4 October 1949) is a Spanish molecular biochemist who discovered the first oncogene HRAS.

Early life and academic career

Barbacid was born in Madrid, Spain on 4 October 1949.[1]

He completed his higher education in the Universidad Complutense de Madrid, where he studied chemical sciences, and in the United States, where he started as an intern; years later he was appointed director of the Developmental Oncology Section of the Basic Research Program at NCI-Frederick, a center associated to the National Cancer Institute. He then moved back to his native Spain to lead the newly created CNIO (Centro Nacional de Investigaciones Oncológicas). He also served on the Life Sciences jury for the Infosys Prize in 2011.

Scientific research

Barbacid is credited for isolating the human oncogene HRAS in bladder carcinoma. His discovery was published in Nature in 1982 in an article titled "A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder-carcinoma oncogene".[2] He spent the following months extending his research, eventually discovering that such oncogene was the mutation of an allele of the Ras subfamily, as well as its activation mechanism.

In 2003, he proved that the enzyme CDK2, until then believed to be indispensable in cellular division, was not necessary in order for DNA replication to take place.[3]

In December 2025, he published a paper in PNAS describing a targeted therapy that successfully regressed pancreatic cancer and prevented tumor resistance in a mouse model.[4] In January 2026, Barbacid and his group at the CNIO published a study in which a combination of three targeted inhibitors, the established drugs afatinib and daraxonrasib, and a compound used for cancer research named SD36, showed promise in treating pancreatic cancer in animal models.[5][6]

Publications

  • "A point mutation is responsible for the acquisition of transforming properties by the T24 Human Bladder-Carcinoma Oncogene." (1982).[2]
  • "Direct mutagenesis of HA-RAS-1 oncogenes by N-Nitroso-N-Methylurea during initiation of mammary carcinogenesis in rats." (1985).[7]
  • "Ras genes." (1987).[8]
  • "The TRK proto-oncogene encodes a receptor for nerve growth-factor." (1991).[9]
  • "trkC, a new member of the trk family of tyrosine protein-kinases, is a receptor for neutotrophin-3." (1991).[10]
  • "Genetic analysis of mammalian cyclin-dependent kinases and their inhibitors." (2000).[11]
  • "Toll-like Receptor-4 (TLR4) Down-regulates MicroRNA-107, Increasing Macrophage Adhesion via Cyclin-dependent Kinase 6." (2011)[12]

Awards

His scientific career has been awarded with prizes such as the Distinguished Young Scientist Award (1983), the King Juan Carlos I Science award (1984), the Rhodes Memorial award (1985) and the Charles Rodolphe Brupbacher (2005). His effort has also been acknowledged with the Great Cross of the Order of 2 May (2011).

Other awards include:

  • King Juan Carlos I Award (Spain, 1984)
  • Rhodes Memorial Award (USA, 1985)
  • Joseph Steiner Award (Switzerland, 1988)
  • IPSEN Prize in neuronal plasticity (Austria, 1994)
  • Charles Rodolphe Brupbacher Cancer Prize (Switzerland, 2005)
  • International Agency for Research on Cancer Medal of Honor (France, 2007)

References

  1. ^ Javier Sampedro (29 September 2009). El País (ed.). "Barbacid deja la dirección del CNIO para centrarse en la investigación". El científico ya expresó su intención de abandonar el cargo tras la puesta en marcha del centro oncológico (in Spanish). Retrieved 29 September 2009.
  2. ^ a b Reddy, E. P.; Reynolds, R. K.; Santos, E.; Barbacid, M. (11 November 1982). "A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene". Nature. 300 (5888): 149–152. doi:10.1038/300149a0. ISSN 0028-0836. PMID 7133135.
  3. ^ Ortega, Sagrario; Prieto, Ignacio; Odajima, Junko; Martín, Alberto; Dubus, Pierre; Sotillo, Rocio; Barbero, Jose Luis; Malumbres, Marcos; Barbacid, Mariano (4 September 2003). "Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice". Nature Genetics. 35 (1): 25–31. doi:10.1038/ng1232. PMID 12923533 – via PubMed.
  4. ^ Barbacid, Mariano (2 December 2025). "A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance". Proceedings of the National Academy of Sciences. 122 (49).
  5. ^ www.axel-k.com; Gil, Pilar (29 January 2026). "The group led by Barbacid at CNIO completely eliminates pancreatic tumours in mice with no resistance developing". CNIO. Retrieved 30 January 2026.
  6. ^ Salido, Rafael (28 January 2026). "Scientists achieve pancreatic tumour regression in breakthrough study". Euronews. Retrieved 30 January 2026.
  7. ^ Zarbl, H.; Sukumar, S.; Arthur, A. V.; Martin-Zanca, D.; Barbacid, M. (30 May 1985). "Direct mutagenesis of Ha-ras-1 oncogenes by N-nitroso-N-methylurea during initiation of mammary carcinogenesis in rats". Nature. 315 (6018): 382–385. doi:10.1038/315382a0. ISSN 0028-0836. PMID 3923365.
  8. ^ Barbacid, M. (1987). "ras genes". Annual Review of Biochemistry. 56: 779–827. doi:10.1146/annurev.bi.56.070187.004023. ISSN 0066-4154. PMID 3304147.
  9. ^ Klein, R.; Jing, S. Q.; Nanduri, V.; O'Rourke, E.; Barbacid, M. (5 April 1991). "The trk proto-oncogene encodes a receptor for nerve growth factor". Cell. 65 (1): 189–197. doi:10.1016/0092-8674(91)90419-y. ISSN 0092-8674. PMID 1849459.
  10. ^ Lamballe, F.; Klein, R.; Barbacid, M. (6 September 1991). "trkC, a new member of the trk family of tyrosine protein kinases, is a receptor for neurotrophin-3". Cell. 66 (5): 967–979. doi:10.1016/0092-8674(91)90442-2. ISSN 0092-8674. PMID 1653651.
  11. ^ Malumbres, M.; Ortega, S.; Barbacid, M. (2000). "Genetic analysis of mammalian cyclin-dependent kinases and their inhibitors". Biological Chemistry. 381 (9–10): 827–838. doi:10.1515/BC.2000.105. ISSN 1431-6730. PMID 11076015.
  12. ^ Hennessy, Elizabeth J.; Sheedy, Frederick J.; Santamaria, David; Barbacid, Mariano; O'Neill, Luke A. J. (22 July 2011). "Toll-like receptor-4 (TLR4) down-regulates microRNA-107, increasing macrophage adhesion via cyclin-dependent kinase 6". The Journal of Biological Chemistry. 286 (29): 25531–25539. doi:10.1074/jbc.M111.256206. ISSN 1083-351X. PMC 3138295. PMID 21628465.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.